Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
暂无分享，去创建一个
A. Casadevall | G. Antonelli | S. Shoham | D. Focosi | F. Maggi | S. McConnell | Guido Antonellli | Fabrizio Maggi | A. Casadevall | Scott McConnell | Guido Antonellli